The Research Animal Support Facility (RASF) has been a shared resource since the original CCSG was awarded in 1975 and exists to support ongoing clinical and basic cancer research involving laboratory animals at MDACC. The RASF has components located in Houston at MDACC (2 campuses), and in Smithville in the Department of Carcinogenesis. All animal facilities are accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International, have Animal Welfare Assurance approval (A3343-01), and are registered as research animal facilities with the United States Department of Agriculture (USDA) (74-R-065). The Research Animal Support Facility Houston (RASFH) is directed by Peggy T. Tinkey, D.V.M. The RASFH encompasses approximately 99,089 sq. ft. of space and provides housing, procedure space, veterinary care, and quality assurance programs for animals used in cancer research. Clinical, surgical, imaging, radiation therapy, and pathology laboratory facilities and services are provided. Existing technical services have been extended to the South Campus facility, and new services added since the last CCSG renewal include computerized animal pedigree and medical history applications, preclinical toxicology services, and increased transportation services. New equipment includes automated multi-species hematology and chemistry analyzers, patient monitoring systems, automated bedding dispensing systems and waste containers, cargo van, and 100 ventilated rodent rack/cage systems. The RASFH has 122 personnel, which includes 11 veterinarians, 2 associate directors, 1 administrator, 2 section managers, 1 project manager, 10 laboratory personnel, 77 animal care personnel, and 17 clerical/support staff. Dr. Tinkey coordinates the daily operations of the RASFH. Five faculty veterinarians direct the 5 service sections that provide facilities, equipment, and services to research animal users. Funding for the RASFH is currently provided by the CCSG (6%), user fees (39%), institutional support (53%) and other funds (2%). In the past 5 years, the RASFH has been used by 319 investigators supporting 20 different CCSG programs. Peer-reviewed investigators represent 92% of the RASFH user utilization. The majority of animals used are genetically engineered mice. In the past 5 years, the daily average cage counts increased 52%, from 13,243 cages in 2002-03 to 20,132 cages of animals in 2006-07. Future plans include renovation and expansion of the South Campus animal facility, and upgrading and implementing computer applications for business operations and preclinical drug development. Additionally, RASF-Houston and Smithville have jointly submitted a startup proposal to develop a Mutant Mouse Pathology Service to serve all MDACC investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-35
Application #
8144401
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-07-01
Budget End
2011-06-30
Support Year
35
Fiscal Year
2010
Total Cost
$1,285,623
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Tayob, Nabihah; Richardson, Peter; White, Donna L et al. (2018) Evaluating screening approaches for hepatocellular carcinoma in a cohort of HCV related cirrhosis patients from the Veteran's Affairs Health Care System. BMC Med Res Methodol 18:1
Caruso, Joseph A; Duong, Mylinh T; Carey, Jason P W et al. (2018) Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res 78:5481-5491
Yu, Wangie; Chen, Yunyun; Dubrulle, Julien et al. (2018) Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism. Sci Rep 8:4306
Tanco, Kimberson; Azhar, Ahsan; Rhondali, Wadih et al. (2018) The Effect of Message Content and Clinical Outcome on Patients' Perception of Physician Compassion: A Randomized Controlled Trial. Oncologist 23:375-382
Elimova, Elena; Wang, Xuemei; Qiao, Wei et al. (2018) Actionable Locoregional Relapses after Therapy of Localized Esophageal Cancer: Insights from a Large Cohort. Oncology 94:345-353
Hoadley, Katherine A; Yau, Christina; Hinoue, Toshinori et al. (2018) Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer. Cell 173:291-304.e6
Ma, Jiacheng; Huo, XiaoJiao; Jarpe, Matthew B et al. (2018) Pharmacological inhibition of HDAC6 reverses cognitive impairment and tau pathology as a result of cisplatin treatment. Acta Neuropathol Commun 6:103
Meisel, Jane; Zhang, Chao; Neely, Cameron et al. (2018) Evaluation of Prognosis in Hormone Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancer With Low Oncotype DX Recurrence Score. Clin Breast Cancer 18:347-352
Williams, Patrick; Basu, Sreyashi; Garcia-Manero, Guillermo et al. (2018) The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia. Cancer :
Koyyalagunta, Dhanalakshmi; Bruera, Eduardo; Engle, Mitchell P et al. (2018) Compliance with Opioid Therapy: Distinguishing Clinical Characteristics and Demographics Among Patients with Cancer Pain. Pain Med 19:1469-1477

Showing the most recent 10 out of 12418 publications